However, the use of neoadjuvant systemic therapy in breast cancer is reported to be considerably low30,31 Conducting an economic evaluation on the use of dual HER2-targeted medicines for neoadjuvant therapy will provide country-context evidence for consideration to support coverage decisions on these effective high-cost targeted medicines in Sri Lanka. This evidence concerns the gene ERBB2 and breast carcinoma.